miR-122、miR-29b与丙型肝炎病毒相关肝细胞癌的研究

肝脏 ›› 2017, Vol. 22 ›› Issue (12): 1117-1119.

miR-122、miR-29b与丙型肝炎病毒相关肝细胞癌的研究

李华民

714000 陕西省渭南市中心医院病理科

收稿日期:2017-06-07 出版日期:2020-06-15 发布日期:2020-06-15
通讯作者: 李华民,Email:lihuamin_1963@papmedi.cn

Received:2017-06-07 Online:2020-06-15 Published:2020-06-15

摘要/Abstract

摘要： 目的探讨miR-122、miR-29b在丙型肝炎病毒感染相关肝病的表达水平及诊断价值。方法入组2013年1月至2016年12月我院收治的丙型肝炎病毒感染相关肝病患者78例[26例慢性丙型肝炎(CHC)、26例肝硬化(LC)、26例肝细胞癌(HCC)]和25名健康志愿者,采用荧光定量PCR检测各组受试者血清miR-122、miR-29b表达水平。结果与对照组相比,丙型肝炎相关肝病(CHC,LC,HCC)组患者血清miR-122的表达水平均升高,HCC组显著高于对照组(P<0.05);3组(CHC,LC,HCC)患者血清miR-29b的表达水平则下降,HCC组显著低于对照组(P<0.05)。HCC组患者血清miR-122/miR-29b的表达水平均与甲胎蛋白(AFP),ALT正相关(P<0.05) ;在区分HCC和健康人群时,miR-122曲线下面积(AUC)为0.766, miR-29b则为0.617,联合miRNAs与AFP联合检测HCC则提供了最高的诊断效能(AUC=1)。结论 mircroRNAs调控异常可能与HCC等许多肝病密切相关,microRNAs在区别HCC患者和健康人群时,诊断价值高,可与AFP联合检测,作为肝病诊断的标记物。

关键词: miR-122, miR-29b, 丙型肝炎, 肝癌

李华民. miR-122、miR-29b与丙型肝炎病毒相关肝细胞癌的研究[J]. 肝脏, 2017, 22(12): 1117-1119.

参考文献

[1] El-Serag HB. Hepatocellular carcinoma. N Engl J Med,2011,365:1118-1127.
[2] Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma. Mol Clin Oncol,2013,1:593-598.
[3] Klingenberg M, Matsuda A, Diederichs S, et al. Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets. J Hepatol,2017,67: 603-618.
[4] Chen XM. MicroRNA signatures in liver diseases. World J Gastroenterol,2009,15:1665-1672.
[5] Nakao K, Miyaaki H, Ichikawa T. Antitumor function of microRNA-122 against hepatocellular carcinoma. J Gastroenterol, 2014,49:589-593.
[6] Xu Y, Bu X, Dai C, et al. High serum microRNA-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients. Tumour Biol, 2015,36:4773-4776.
[7] Bandiera S, Pfeffer S, Baumert TF, et al. miR-122-a key factor and therapeutic target in liver disease. J Hepatol,2015,62:448-457.
[8] Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med,2013,368:1685-1694.
[9] El-Garem H, Ammer A, Shehab H, et al. Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. World J Hepatol,2014,6:818-824.
[10] Varnholt H, Drebber U, Schulze F, et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology,2008,47:1223-1232.
[11] Chang J, Nicolas E, Marks D, et al. miR-122, a Mammalian Liver-specific microRNA, is processed from hcr mRNA and MayDownregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol, 2004,1:106-113.
[12] Girard M, Jacquemin E, Munnich A, et al. miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol,2008,48:648-656.
[13] Maurer B, Stanczyk J, Jungel A, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum,2010,62:1733-1743.
[14] Ogawa T, Iizuka M, Sekiya Y, et al. Suppression of type I collagen production by microRNA-29b in cultured human stellate cells. Biochem Biophys Res Commun,2010,391:316-321.
[15] Xiong Y, Fang JH, Yun JP, et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology,2010,51:836-845.